The results revealed significant differences in IDH1 mutation and 1P19q codeletion status between PCK2 low and PCK2 high group (p-value < 0.05) in both two datasets, indicating a potential association of high PCK2 expression with IDH1 wildtype or 1P19Q non codeletion (Table 1 and 2), which are both unfavorable clinical characteristics for glioma patients. This evidence concerns the gene PCK2 and central nervous system cancer.